Hengrui Medicine (01276.HK): SHR-6914 Injection Approved for Clinical Trials
NewTimeSpace News: On June 16, 2026, Hengrui Medicine (01276.HK) released an overseas regulatory announcement. SHR-6914 Injection of its subsidiary Suzhou Shengdiya Biomedicine Co., Ltd. has been granted the Drug Clinical Trial Approval Notice approved and issued by the National Medical Products Administration, authorizing clinical research of this product as a single agent for prostate cancer treatment.
The Company stated that after obtaining clinical trial approval, the drug still needs to complete clinical trials and pass review and approval by the National Medical Products Administration before commercial launch. Drug development features a long cycle and multiple procedures with inherent uncertainties, and investors are reminded to exercise caution with relevant risks.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Hengrui Medicine (01276.HK) Adebrelimab Becomes First Domestic PD-L1 Inhibitor for NSCLC Perioperative Setting
- Hengrui Medicine (01276.HK): Marketing Authorization Application for Relugolix Tablets Accepted by EMA
- CMA LOGISTICS (01292.HK): changes English company name and stock short name, to trade as "CM LOGISTICS" from 27 August
- HENGRUI PHARMA (01276.HK): SHR-7012 Injection Receives Clinical Trial Approval for Treating Cutaneous Lupus Erythematosus
- GF SEC (01776.HK): 2025 short-term corporate bond (Tranche 8) "25GFD10" to be redeemed with interest and delisted on 24 August
